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Abstract
Intensity-modulated radiation therapy (IMRT), an innovative treatment option for prostate cancer, 
has rapidly diffused over the past decade. To inform our understanding of racial disparities in 
prostate cancer treatment and outcomes, this study compared diffusion of IMRT in African 
American (AA) and Caucasian American (CA) prostate cancer patients during the early years of 
IMRT diffusion using the Surveillance, Epidemiology and End Results (SEER)–Medicare linked 
database. A retrospective cohort of 947 AA and 10,028 CA patients diagnosed with localized 
prostate cancer from 2002 through 2006, who were treated with either IMRT or non-IMRT as 
primary treatment within 1 year of diagnoses was constructed. Logistic regression was used to 
examine potential differences in diffusion of IMRT in AA and CA patients, while adjusting for 
socioeconomic and clinical covariates. A significantly smaller proportion of AA compared with 
CA patients received IMRT for localized prostate cancer (45% vs. 53%, p < .0001). Racial 
differences were apparent in multivariable analysis though did not achieve statistical significance, 
as time and factors associated with race (socioeconomic, geographic, and tumor related factors) 
explained the preponderance of variance in use of IMRT. Further research examining improved 
access to innovative cancer treatment and technologies is essential to reducing racial disparities in 
cancer care.
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Introduction
African American (AA) men in the United States experience significantly greater prostate 
cancer incidence and mortality compared with Caucasian American (CA) males (American 
Cancer Society, 2013a, 2013b). The reasons for this disparity are complex and not fully 
understood, but are believed to include differential access to care, including differences in 
cancer treatment (American Cancer Society, 2013b). Prior studies have demonstrated that 
compared with CA men, AA men are diagnosed at a later stage (Cohen et al., 2006; Du et 
al., 2006; Hoffman et al., 2001; Mullins, Onukwugha, Bikov, Seal, & Hassain, 2010) receive 
less aggressive treatment (Ellis et al., 2013; Godley et al., 2003; Hayn et al., 2011; Holmes 
et al., 2009; Pisu et al., 2010) and also experience a longer delay from diagnosis to start of 
treatment (Gross, Smith, Wolf, & Andersen, 2008; Stokes et al., 2013).
Treatment options for prostate cancer differ depending on the age and general health of the 
patient, and the characteristics of the cancer itself. The primary treatment options for early-
stage disease—which is the focus of this study—include prostatectomy (surgical removal of 
the prostate gland), brachytherapy (surgical implantation of radioactive seeds), and external 
beam radiation therapy. Because these prostate cancer treatment options show comparable 
survival benefits and there is no definitive “best” treatment, treatment selection is commonly 
a matter of the patient's preference and his physician's referral.
In addition, within the treatment options of prostatectomy, brachytherapy, and radiation—
there has been dramatic technological advancements over the past 15 years. For radiation 
therapy the advent of computed tomography–based treatment planning, three-dimensional 
conformal radiotherapy allowed for a higher dose of radiation to be delivered to the prostate 
safely compared with the previous technology of two-dimensional radiation planning 
(Cahlon, Hunt, & Zelefsky, 2008). More recent, the advent of more sophisticated treatment 
planning and delivery, namely intensity-modulated radiation therapy (IMRT; Cahlon et al., 
2008; De Meerleer et al., 2000; Ling et al., 1996; Sheets, Hendrix, Allen, & Chen, 2013) 
further reduces unnecessary radiation exposure to organs and tissue adjacent to the prostate 
(Cahlon et al., 2008; De Meerleer et al., 2000; Ling et al., 1996). Compared with the older 
conformal radiotherapy, IMRT has been demonstrated to be more effective in treating 
prostate cancer and causes fewer side effects (Forsythe, Blacksburg, Stone, & Stock, 2012; 
Sheets et al., 2012).
The use of IMRT technology for the treatment of prostate cancer has diffused rapidly over 
the past decade, and is now the standard type of radiation used to treat this disease (Jacobs et 
al., 2012a, 2012b); however, the evenness of its uptake among all men with prostate cancer 
remains unknown. Slower uptake of this more effective radiation technology among AA 
men with prostate cancer may explain, in part, the racial disparity in prostate cancer 
outcomes. In this study, data from the Surveillance, Epidemiology, and End Results (SEER)
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—Medicare linked database were analyzed to examine diffusion of IMRT in CA and AA 
patients with prostate cancer. Given the disparities in access to care and treatment for AA 
patients as reviewed above, this study hypothesized that there was slower diffusion of IMRT 
among AA patients.
Method
Data Source
A population-based retrospective cohort was created from SEER-Medicare data. The linkage 
of the SEER and Medicare data is the result of the collaborative effort of the National 
Cancer Institute (NCI), the SEER registries, and the Center for Medicare and Medicaid 
Services (Warren, Klabunde, Schrag, Bach, & Riley, 2002). The SEER-Medicare database is 
composed of 16 population-based cancer registries that represent approximately 26% of the 
U.S. population, linked to health care utilization data from Medicare, which provides 
benefits to 97% of the U.S. population ≥65 (Sheets et al., 2013).
Study Cohort
The study cohort included AA and CA men 66 years and older (to allow at least 1 year of 
Medicare claims before diagnosis for calculation of a comorbidity score; Klabunde, Legler, 
Warren, Baldwin, & Schrag, 2007; Stokes et al., 2013), who received radiation treatment for 
prostate cancer between 2002 and 2006, the early years of IMRT diffusion (Sheets et al., 
2012; Sheets et al., 2013; Stokes et al., 2013). Men with additional cancer diagnoses, 
metastatic disease, disease diagnosed at autopsy, and those missing month of diagnosis were 
excluded. Additionally, men enrolled in a health maintenance organization and those who 
were not enrolled in both Medicare Part A and Part B, from 1 year before to 1 year after 
diagnosis were excluded, to ensure complete capture of health services. The final analytic 
cohort included 10,975 AA and CA patients.
Outcomes
The primary outcome of this study was receipt of IMRT, which was determined using the 
Current Procedural Terminology/Healthcare Common Procedure Coding System procedure 
codes, and International Classification of Disease–Ninth Revision codes:
IMRT: G0174, G0178, 77418, 0073T
Non-IMRT: 77305, 77310, 77315, 77321, 77371, 77372, 77373, 77402, 77403, 
77404, 77406, 77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 77422, 
77423, 92.24, 92.26, 77301, 77418, 0073T, 77380, 77381, 77520, 77522, 77523, 
and 77525
Covariates
Demographic characteristics, including race, age, year of radiation treatment, martial status, 
census tract–level education/income, NCI combined comorbidity score, and population 
density were obtained from SEER. SEER regions were grouped into Northeast (Connecticut, 
New Jersey), South (Atlanta, rural Georgia, Kentucky, Louisiana), Central (Detroit, Iowa, 
New Mexico, Utah), and West (San Francisco, Hawaii, Seattle, San Jose, Los Angeles, 
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greater California). Medicare claims data from 12 months preceding prostate cancer 
diagnosis were used to obtain a comorbidity score validated specifically for claims data 
(Stokes et al., 2013). Clinical stage were group T1/T2 (well and moderately differentiated) 
and T3/T4 (poorly differentiated and undifferentiated).
Statistical Analysis
Pearson chi-square tests were used to evaluate differences in baseline demographics and 
treatment by race. Logistic regression was used to examine potential difference in receipt of 
IMRT in AA and CA patients, while adjusting for age of diagnosis (66-69, 70-74, ≥75 
years), year of radiation treatment, marital status, census-tract educational attainment, 
population density (urban or rural), and SEER region. Potential interaction terms race * year 
of radiation treatment, race * region, race * urban–rural, race * age, and age * marital status 
were examined. Statistical significance was set at p < .05; all tests were two-tailed. Analyses 
were performed using SAS Version 9.3 (SAS Institute, Cary, NC). Approval from the 
University of North Carolina at Chapel Hill Institutional Review Board was waived.
Results
Table 1 summarizes the demographic and clinical characteristics of the analytic cohort, 
which included 947 AA and 10,028 CA patients. Compared with AA patients, a greater 
proportion of CA patients received IMRT (53% vs. 45%, p < .0001). More AA men than CA 
men were not married, lived in areas with lower income/educational attainment, and had 
higher comorbidity scores.
Table 2 examines receipt of IMRT by patient characteristics, stratified by race. In both AA 
and CA men, IMRT use in creased from 2002 to 2006: AA from 8% to 82% (p < .0001) and 
CA from 16% to 88% (p < .0001). There was also significant regional variation in IMRT use 
for both AA and CA patients, with highest use in the West and Northeast, and higher IMRT 
use associated with areas with higher income.
On multivariate analysis (Table 3), a lower comorbidity score was associated with receipt of 
IMRT. There was significant geographic variation in diffusion of IMRT, including 
differential use by SEER region, race, urban/rural residence, living in areas with different 
regional educational attainment, and age at diagnosis.
Overall, AA race was associated with less use of IMRT (crude OR = 0.73, p < 0.0001). 
Racial differences were similar in multivariable analysis though did not achieve statistical 
significance (OR = 0.95, p < 0.54); data in supplementary analysis). In analytic models 
testing varying degrees of specification, the preponderance of variance in use of IMRT was 
explained by time and socioeconomic, geographic, and tumor-related factors (Table 3). Of 
the tested interaction terms, only Race(AA)*Urban residence was significant and therefore 
retained in the final model. Examining the interaction effects, the OR for AA vs. CA use of 
IMRT was smaller for urban areas (OR = 0.2) than in rural areas (OR = 0.88, derived from 
0.2 * 4.4), suggesting that racial disparities may differ between urban and rural areas
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Discussion
The use of IMRT was less common in AA compared with CA patients (Figure 1, Table 2). 
Multivariable analysis indicated that this disparity is likely more a function of factors that 
research has shown to be associated with AA race rather than race alone. Specifically, there 
was significant geographic variation in diffusion of IMRT, including differential use by 
SEER region, race, urban/rural residence, and living in areas with different regional 
educational attainment. Although racial disparity in prostate cancer treatment and outcomes 
is well described (Cohen et al., 2006; Du et al., 2006; Ellis et al., 2013; Godley et al., 2003; 
Hayn et al., 2011; Shavers et al., 2004; Tyson & Castle, 2014), this is the first population-
based study to examine whether such disparity exists in diffusion of innovative treatment 
technology.
The geographic variation in IMRT diffusion is not surprising. Compared with older radiation 
technology (three-dimensional conformal radiation), IMRT is considerably more expensive, 
and upgrading equipment to allow IMRT can cost more than a million dollars (Ellis et al., 
2013; Nguyen et al., 2011; Roberts et al., 2013). Because of the significant capital required 
to purchase the infrastructure to deliver IMRT, this technology may not be evenly adopted in 
clinical settings (Jacobs et al., 2012a, 2012b). The descriptive statistics (Table 2) and 
regression results (Table 3) suggest that AAs live in lower socioeconomic areas with 
significantly lower incomes. It may be that this corresponds to lower reimbursement for 
radiation therapy providers, which therefore have fewer financial resources and are not able 
to reinvest in capital improvements—namely, new IMRT technology—as rapidly as areas of 
greater wealth and greater health care reimbursement. In the higher socioeconomic regions, 
health care providers may simultaneously experience greater competition for lucrative payer 
contracts, and may be even more likely to rapidly adopt innovative technologies as they 
compete on innovation and state-of-the-art care to win those contracts. This corresponds to 
research by Jacobs et al. (2012b) who examined the association between managed care 
penetration in health care markets and diffusion of IMRT. The authors reported that markets 
with the highest managed care penetration delivered IMRT more rapidly than those without 
penetration. This may explain the greater proportion of IMRT diffusion observed in the 
current study for AA and CA men in the West.
In so far as AA men were more likely than CA men to live in areas such as the South and 
urban areas that were slower to adopt IMRT, they were also less likely to receive this newer 
treatment. In addition, the racial differences in IMRT use by urban/rural location (Table 2, 
Table 3) merit close examination in future research to differentiate whether these are a 
function of factors amenable to intervention, or other more challenging factors including 
inherent biases.
Whether there is a differential diffusion of innovative cancer treatment by patient subgroups 
including race has not been well studied. The current findings are similar with those reported 
by Reeder-Hayes et al. (2011), who identified significant disparities in the receipt of sentinel 
lymph node biopsy, an innovative and morbidity-sparing procedure for early-stage breast 
cancer, among vulnerable populations, including AA women. In another study, Meyer et al. 
(2013), examined whether organizational research and teaching affiliation were associated 
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with accelerated diffusion of sentinel lymph node biopsy, and reported that women receiving 
surgery at institutions affiliated with NCI cooperative groups were more likely to receive 
sentinel lymph node biopsy compared with women treated at nonaffiliated organizations.
The current results and those reported by Meyer et al. (2013), suggest that one way to reduce 
disparities in cancer treatment, specifically related to receipt of innovative treatments and 
technologies, may be to improve access to these treatments for minority patients living in the 
South, areas that have a high proportion of minority patients, or receiving treatment in 
organizations that were found to slowly adopt new treatment technology. Operationalizing 
this concept has always been challenging. Opportunities may include enhanced partnerships 
between academic and tertiary care centers—historically sites of innovation discovery and 
early adoption—and historically slower adopting centers. Such partnerships may mirror 
those embraced by the NCI's Community Clinical Oncology Program, which has promoted 
the two-way communication and collaboration between academic centers and community-
based practices for the purpose of communicating research-based innovations, informing the 
development of research that is not only innovative but also practical, and developing 
mutually agreeable referral relationships both for clinical research and clinical care 
(Minasian et al., 2010). Such affiliation relationships may promote critical injections of 
necessary capital to acquire the innovative technology, and medical education to facilitate 
medical training in its appropriate use. It may also help identify alternative routes for 
acquisition of resources, such as through grants and government subsidies, that may have 
been unknown previously by the community center. This study only sought to identify 
whether there was a racial disparity in receipt of this innovative technology, and to gain 
preliminary insight into its causes. Future research should seek to more qualitatively identify 
the causal factors for this disparity, and in doing so identify tractable solutions for resolving 
it.
There are several limitations of this study. The study was a population-based retrospective 
cohort using SEER-Medicare, and therefore the results may not be generalizable to younger 
populations (Warren et al., 2002). However, because the median age at the time of prostate 
cancer diagnosis is 68 years (American Cancer Society, 2010), this study is applicable to the 
vast majority of patients who receive radiation therapy for prostate cancer. SEER-Medicare 
data also have limited person-level data on socioeconomic variables, and instead rely on 
Census measures of income and education at the local level. In addition, small cell sizes for 
some measures challenge our ability to conduct more nuanced examinations of the details or 
underpinnings of the observed associations, including the apparent associations between 
race, region, and urban/rural residence. Accordingly, future should seek to examine these 
factors at the person-level, which may clarify which are the key components of the often-
conflated measures of race, education, and income, which are all associated with differential 
access to care (Stokes et al., 2013). The strength of using SEER-Medicare data for this 
current study is the population-based design and the large number of patients included, 
allowing findings of this study to be reflective of practice patterns across the United States.
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Conclusions
A greater proportion of CA patients, compared with AA patients received IMRT during the 
early years of diffusion for this innovative radiation technology. There was significant 
geographic variation in diffusion of IMRT, including differential use by SEER region, race, 
urban/rural residence, living in areas with different regional educational attainment, and age 
at diagnosis. Further research is needed to directly examine whether efforts targeting specific 
areas to improving access to innovative cancer treatment and technologies can reduce or 
eliminate the racial disparities in cancer care.
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Figure I. 
Diffusion of intensity-modulated radiation therapy (IMRT) by race, 2002-2006 (n = 5,705).
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Table 1
Demographic and Clinical Characteristics by Race, SEER-Medicare 2002-2006.
Characteristics AA (N = 947); n (%) CA (N = 10,028); n (%) p
Age at diagnosis (years) <.0001
    66-69 256 (27) 1,907 (19)
    70-74 362 (38) 3,651 (36)
    ≥75 329 (35) 4,470 (45)
Year of radiation .977
    2002 212 (22) 2,198 (22)
    2003 191 (20) 2,109 (20)
    2004 178 (19) 1,863 (19)
    2005 180 (19) 1,876 (19)
    2006 186 (20) 1,982 (20)
Marital status <.0001
    Married 535 (56) 7,295 (73)
    Not married/unknown 412 (44) 2,733 (37)
NCI combined comorbidity score <.0001
    0 478 (50) 6,327 (63)
    >0 469 (50) 3,701 (37)
% census income <.0001
    0%-25% (low income) 566 (60) 2,256 (22)
    26%-50% (low–medium income) 209 (22) 2,638 (26)
    51%-75% (medium–high income) 122 (13) 2,567 (26)
    >75% (High income) 50 (5) 2,567 (26)
% non–high school graduate in census tract <.0001
    0%-25% (low education) 550 (58) 2,157 (22)
    26%-50% (low–medium education) 218 (23) 2,459 (25)
    51%-75% (medium–high education) 129 (14) 2,756 (27)
    >75% (high education) 50 (5) 2,656 (26)
Population density .038
    Urban 898 (95) 8,845 (88)
    Rural 49 (5) 1,183 (12)
Tumor grade
    I 478 (50) 4,507 (45) .002
    II 443 (47) 5,127 (51)
    III/IV 26 (3) 394 (4)
Clinical stage .399
    T1/T2 516 (54) 5,607 (56)
    T3/T4 431 (45) 4,421 (44)
Treatment modality <.0001
    IMRT 423 (45) 5,282 (53)
    CRT 524 (55) 4,746 (47)
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Characteristics AA (N = 947); n (%) CA (N = 10,028); n (%) p
Geographic region <.0001
    South 252 (26) 1,604 (16)
    Northeast 280 (30) 2,871 (29)
    Central 272 (29) 2,108 (21)
    West 143 (15) 3,445 (34)
Note. SEER = Surveillance, Epidemiology, and End Results; AA = African American; CA = Caucasian; NCI = National Cancer Institute; IMRT = 
intensity-modulated radiation therapy; CRT = conformal radiation therapy. SEER sites were grouped into four geographic regions for analysis.
a. Determined using the chi-square test.
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Table 2
Demographic and Clinical Characteristics by Race and Treatment Modality, SEER-Medicare 2002-2006.
AA (N = 947) CA (N = 10,028)
CRT (n = 524) IMRT (n = 423) CRT (n = 4,746) IMRT (n = 
5,282)
Characteristics No. (%)a No. (%)a P No. (%)a No. (%)a P
Age at diagnosis (years) .530 .781
    66-69 134 (52) 122 (48) 889 (47) 1,018 (53)
    70-74 204 (56) 158 (44) 1,737 (48) 1,914 (52)
    ≥75 186 (56) 143 (44) 2,120 (47) 2,350 (53)
Year of radiation <.0001 <.0001
    2002 196 (92) 16 (8) 1,845 (84) 353 (16)
    2003 138 (72) 53 (28) 1,399 (66) 710 (34)
    2004 97 (54) 81 (46) 837 (45) 1,026 (55)
    2005 59 (33) 121 (67) 432 (23) 1,444 (77)
    2006 34 (18) 152 (82) 233 (12) 1,749 (88)
Marital status .146 .876
    Married 285 (53) 250 (47) 3,456 (47) 3,839 (53)
    Not married/unknown 239 (58) 173 (42) 1,290 (47) 1,443 (53)
NCI combined comorbidity score .215 .0003
    0 255 (53) 223 (47) 2,908 (46) 3,419 (54)
    >0 269 (57) 200 (43) 1,838 (50) 1,863 (50)
% census income .023 <.0001
    0%-25% (low income) 328 (58) 238 (42) 1,232 (55) 1,024 (45)
    26%-50% (low–medium income) 119 (57) 90 (43) 1,332 (51) 1,306 (49)
    51%-75% (medium–high income) 55 (45) 67 (55) 1,161 (45) 1,406 (55)
    >75% (high income) 22 (44) 28 (56) 1,021 (40) 1,546 (60)
% non–high school graduate in census tract .127 <.0001
    0%-25% (low education) 312 (57) 238 (43) 1,230 (57) 927 (43)
    26%-50% (low–medium education) 127 (58) 91 (42) 1,232 (50) 1,227 (50)
    51%-75% (medium–high education) 62 (48) 67 (52) 1,247 (45) 1,509 (55)
    >75% (high education) 23 (46) 27 ( 54) 1,037 (39) 1,619 (61)
Population density .007 <.0001
    Urban 506 (56) 392 (44) 4,011 (45) 4,834 (55)
    Rural 18 (37) 31 (63) 735 (62) 448 (38)
Tumor grade <.0001 <.0001
    I 237 (50) 241 (50) 1,850 (41) 2,657 (59)
    II 274 (62) 169 (38) 2,685 (52) 2,442 (48)
    III/IV 13 (50) 13 (50) 211 (54) 183 (46)
Clinical stage .0003 <.0001
    T1/T2 313 (60) 203 (39) 2,883 (61) 3,240 (52)
    T3/T4 211 (49) 220 (51) 1,863 (39) 2,989 (48)
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AA (N = 947) CA (N = 10,028)
CRT (n = 524) IMRT (n = 423) CRT (n = 4,746) IMRT (n = 
5,282)
Characteristics No. (%)a No. (%)a P No. (%)a No. (%)a P
Geographic region <.0001 <.0001
    South 133 (53) 119 (47) 900 (56) 704 (44)
    Northeast 133 (48) 147 (52) 1,086 (38) 1,785 (62)
    Central 193 (71) 79 (29) 1,263 (60) 845 (40)
    West 65 (45) 78 (55) 1,497 (43) 1,948 (57)
Note. SEER = Surveillance, Epidemiology, and End Results; AA = African American; CA = Caucasian; NCI = National Cancer Institute; IMRT = 
intensity-modulated radiation therapy; CRT = conformal radiation therapy. SEER sites were grouped into four geographic regions for analysis.
a
Determined using the chi-square test.
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Table 3
Multivariate Logistic Regression Models for Evaluating Predictors of IMRT Diffusion, SEER-Medicare 
2002-2006.
Adjusted predictors for IMRT diffusiona
Characteristics OR 95% CI P
Race
    CA 1.00 Reference —
    AA (urban only) 0.20 [0.09, 0.42] <.0001
Age at diagnosis, (years)
    66-69 1.00 Reference —
    70-74 0.99 [0.87, 1.13] .921
    ≥75 0.93 [0.82, 1.05] .0.252
Year of radiation
    2002 1.00 Reference —
    2003 2.93 [2.53, 3.39] <.0001
    2004 7.69 [6.62, 8.94] <.0001
    2005 22.40 [19.03, 26.37] <.0001
    2006 52.00 [43.31, 62.43] <.0001
Marital status
    Married 1.00 Reference —
    Not married/unknown 1.00 [0.95, 1.05] .0987
NCI combined comorbidity score
    0 1.00 Reference —
    >0 0.82 [0.74, 0.90] <.0001
Income (census tract)
    Quartile 1 (0%-25%) 1.00 Reference —
    Quartile 2 (26%-50%) 1.04 [0.90, 1.21] .575
    Quartile 3 (51%-75%) 1.18 [1.00, 1.38] .0.0496
    Quartile 4 (76%-100%) 1.21 [0.99, 1.47] .061
Education (census tract)
    Quartile 1 (0-%25%) 1.00 Reference —
    Quartile 2 (26%-50%) 1.30 [1.12, 1.50] .0006
    Quartile 3 (51%-75%) 1.69 [1.43, 2.00] <.0001
    Quartile 4 (76%-100%) 2.28 [1.87, 2.77] <.0001
Population density
    Urban 1.00 Reference —
    Rural 0.17 [0.08, 0.37] <.0001
Tumor grade
    I 1.00 Reference —
    II 0.95 [0.87, 1.05] .374
    III/IV 0.81 [0.63, 1.04] .099
Clinical stage
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Adjusted predictors for IMRT diffusiona
Characteristics OR 95% CI P
    T1/T2 1.00 Reference —
    T3/T4 0.91 [0.87-0.96] .0003
Geographic region
    South 1.00 Reference —
    Northeast 2.38 [2.05, 2.76] <.0001
    Central 0.90 [0.77, 1.04] .159
    West 1.77 [1.53, 2.04] <.0001
Interaction terms
    Race (AA) * Urban 4.39 2.17-8.89 <.0001
Note. NCI = National Cancer Institute; SEER = Surveillance, Epidemiology, and End Results; 95% CI = confidence interval; OR = odds radio; AA 
= African American; CA = Caucasian; IMRT = intensity-modulated radiation therapy. SEER sites were grouped into four geographic regions for 
analysis.
a
Logistic regression adjusted for race, age (3 categories), year of radiation, marital status, Charlson comorbidity index, income, education, 
population density, tumor grade, clinical stage, geographic region, and race (AA) * urban.
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